- Home
- ADAG vs CHAI Comparison
ADAG vs CHAI Comparison
Compare ADAG & CHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- CHAI
- Stock Information
- Founded
- ADAG 2011
- CHAI 2024
- Country
- ADAG China
- CHAI United States
- Employees
- ADAG N/A
- CHAI N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- CHAI Telecommunications Equipment
- Sector
- ADAG Health Care
- CHAI Telecommunications
- Exchange
- ADAG Nasdaq
- CHAI Nasdaq
- Market Cap
- ADAG 110.8M
- CHAI 122.3M
- IPO Year
- ADAG 2021
- CHAI N/A
- Fundamental
- Price
- ADAG $1.79
- CHAI $4.80
- Analyst Decision
- ADAG Strong Buy
- CHAI
- Analyst Count
- ADAG 3
- CHAI 0
- Target Price
- ADAG $7.67
- CHAI N/A
- AVG Volume (30 Days)
- ADAG 78.0K
- CHAI 675.7K
- Earning Date
- ADAG 08-12-2025
- CHAI 11-13-2025
- Dividend Yield
- ADAG N/A
- CHAI N/A
- EPS Growth
- ADAG N/A
- CHAI N/A
- EPS
- ADAG N/A
- CHAI N/A
- Revenue
- ADAG $103,204.00
- CHAI N/A
- Revenue This Year
- ADAG $7,411.34
- CHAI N/A
- Revenue Next Year
- ADAG $28.29
- CHAI N/A
- P/E Ratio
- ADAG N/A
- CHAI N/A
- Revenue Growth
- ADAG N/A
- CHAI N/A
- 52 Week Low
- ADAG $1.33
- CHAI $3.72
- 52 Week High
- ADAG $3.16
- CHAI $60.40
- Technical
- Relative Strength Index (RSI)
- ADAG 41.71
- CHAI N/A
- Support Level
- ADAG $1.75
- CHAI N/A
- Resistance Level
- ADAG $1.95
- CHAI N/A
- Average True Range (ATR)
- ADAG 0.12
- CHAI 0.00
- MACD
- ADAG -0.01
- CHAI 0.00
- Stochastic Oscillator
- ADAG 20.32
- CHAI 0.00
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.